The company is building a low-cost diagnostic technology designed to identify Alzheimer’s disease up to 15 years before symptoms appear — a breakthrough that could reshape how neurodegenerative diseases are detected and managed in India.

 

The newly raised capital will help eNLife expand its research and development team in Bengaluru, strengthen its biomarker discovery platform, and advance its first diagnostic assay from prototype development to clinical-grade validation.

 

Over the next 9 to 18 months, the company also plans to begin filing patents covering its biomarker binders, diagnostic assays, and detection platform.

 

Founded by Deepak Kumaran Nair (Professor, Centre for Neuroscience, IISc), Lt Col Jojo Jacob (Veteran), and Anish Mathew (Ex CEO, CAMS Finserv, a Subsidiary of CAMS Group), eNLife is developing a blood-based diagnostic test that screens for a panel of five to seven biomarkers linked to Alzheimer’s onset, including amyloid beta and harmful forms of tau — two proteins closely associated with Alzheimer’s pathology.

 

Beyond Alzheimer’s, the company is developing next-generation assays capable of analysing 25 to 100 biological markers simultaneously, with the goal of identifying multiple forms of dementia and other neurodegenerative diseases before clinical symptoms appear.

 

The startup’s approach aims to overcome the limitations of existing diagnostic methods such as PET scans, MRIs, and cerebrospinal fluid analysis, which can be expensive, invasive, and often used only after significant disease progression. eNLife’s platform is designed for use through routine diagnostic centres, with results expected within two to five hours.

 

At the core of the platform is an AI engine trained to detect complex relationships between biomarkers and identify early disease progression signals years before cognitive decline becomes visible.

 

eNLife is working with researchers associated with leading institutions including the Indian Institute of Science (IISc), the National Institute of Mental Health and Neurosciences (NIMHANS), the Tata Institute of Fundamental Research (TIFR), Hyderabad, and the Centre for Brain Research (CBR), Bengaluru, to develop India-specific biomarker datasets.

 

The company says its focus addresses a critical gap in existing diagnostic models, which have largely been developed using Western population datasets. Differences in genetics, lifestyle, and risk factors among Indian patients can influence disease patterns and diagnostic accuracy.

 

Commenting on the funding, Deepak Kumaran Nair, Co-founder and CEO, eNLife Research said, "The biggest failure of Alzheimer's care today isn't the absence of treatments in trials; it's that we find patients a decade too late to use them. Every diagnostic model the world has built so far was designed on Western cohorts, at hospital price points that don't work for India.